Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | President, Cell Therapy Org. | March 10, 2026 | March 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date March 10, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 8,210 |
Ending reported balance
After 2026-03-10 transaction · row 9
9 source rows · reconciled sequenceRow 1 · 2026-03-10 · Exercise / conversion · Acquired 838 · Balance 5,549 F1: Represents vesting of one-quarter of market share units granted on March 10, 2022. Row 2 · 2026-03-10 · Other · Disposed 94 · Balance 5,455 F2: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Row 3 · 2026-03-10 · Tax withholding · Disposed 212 · Balance 5,243 F3: Shares withheld for payment of taxes upon vesting of awards. Row 4 · 2026-03-10 · Exercise / conversion · Acquired 1,050 · Balance 6,293 F4: Represents vesting of one-quarter of market share units granted on March 10, 2023. Row 5 · 2026-03-10 · Other · Disposed 113 · Balance 6,180 F2: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Row 6 · 2026-03-10 · Tax withholding · Disposed 267 · Balance 5,913 F3: Shares withheld for payment of taxes upon vesting of awards. Row 7 · 2026-03-10 · Exercise / conversion · Acquired 6,304 · Balance 12,217 F5: Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award. Row 8 · 2026-03-10 · Other · Disposed 3,095 · Balance 9,122 F6: Adjustment to award based on the performance factor applied in accordance with the terms of the award and certification of performance results by the Board. Row 9 · 2026-03-10 · Tax withholding · Disposed 912 · Balance 8,210 F3: Shares withheld for payment of taxes upon vesting of awards. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2026-03-10 | Direct | 0 |
Reported balance
After 2026-03-10 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-03-10 · Exercise / conversion · Disposed 838 · Balance 0 F7: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F1: Represents vesting of one-quarter of market share units granted on March 10, 2022. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2027-03-10 | Direct | 1,052 |
Reported balance
After 2026-03-10 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-03-10 · Exercise / conversion · Disposed 1,050 · Balance 1,052 F7: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F4: Represents vesting of one-quarter of market share units granted on March 10, 2023. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2029-03-10 | Direct | 6,531 |
Reported balance
After 2026-03-10 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-03-10 · Grant · Acquired 6,531 · Balance 6,531 F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout. F10: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2026-03-10 | Direct | 0 |
Reported balance
After 2026-03-10 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-03-10 · Exercise / conversion · Disposed 6,304 · Balance 0 F8: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2026. F5: Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2029-03-10 | Direct | 9,796 |
Reported balance
After 2026-03-10 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-03-10 · Grant · Acquired 9,796 · Balance 9,796 F11: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents vesting of one-quarter of market share units granted on March 10, 2022.
F2: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor.
F3: Shares withheld for payment of taxes upon vesting of awards.
F4: Represents vesting of one-quarter of market share units granted on March 10, 2023.
F5: Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award.
F6: Adjustment to award based on the performance factor applied in accordance with the terms of the award and certification of performance results by the Board.
F7: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%.
F8: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2026.
F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout.
F10: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board.
F11: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2026 Filed Mar 12, 2026 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 9,796 | $0.00 | $0.00 |
DisclosureSEC source: 0002005382-26-000002 · wk-form4_1773346616.xml · derivative · entry 14 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,796 Underlying: Common Stock, $0.10 par value · 9,796 shares Expires 2029-03-10 F11 · derivative.exercise_price: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board. F11 · derivative.exercise_date: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 6,531 | $0.00 | $0.00 |
DisclosureSEC source: 0002005382-26-000002 · wk-form4_1773346616.xml · derivative · entry 13 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,531 Underlying: Common Stock, $0.10 par value · 6,531 shares Expires 2029-03-10 F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout. F10 · derivative.exercise_date: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 6,304 | $0.00 | $0.00 |
DisclosureSEC source: 0002005382-26-000002 · wk-form4_1773346616.xml · derivative · entry 12 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 6,304 shares Expires 2026-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2026. F5 · derivative.exercise_date: Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 1,050 | $0.00 | $0.00 |
DisclosureSEC source: 0002005382-26-000002 · wk-form4_1773346616.xml · derivative · entry 11 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,052 Underlying: Common Stock, $0.10 par value · 1,050 shares Expires 2027-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F4 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2023. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 838 | $0.00 | $0.00 |
DisclosureSEC source: 0002005382-26-000002 · wk-form4_1773346616.xml · derivative · entry 10 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 838 shares Expires 2026-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F1 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2022. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 912 | $60.13 | $54,838.56 |
DisclosureSEC source: 0002005382-26-000002 · wk-form4_1773346616.xml · nonDerivative · entry 9 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,210 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 3,095 | $0.00 | $0.00 |
DisclosureSEC source: 0002005382-26-000002 · wk-form4_1773346616.xml · nonDerivative · entry 8 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,122 F6 · shares: Adjustment to award based on the performance factor applied in accordance with the terms of the award and certification of performance results by the Board. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 6,304 | $0.00 | $0.00 |
DisclosureSEC source: 0002005382-26-000002 · wk-form4_1773346616.xml · nonDerivative · entry 7 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Amount represents distribution of performance shares earned under the 2023-2025 Long-Term Performance Award. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 267 | $60.13 | $16,054.71 |
DisclosureSEC source: 0002005382-26-000002 · wk-form4_1773346616.xml · nonDerivative · entry 6 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,913 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 113 | $0.00 | $0.00 |
DisclosureSEC source: 0002005382-26-000002 · wk-form4_1773346616.xml · nonDerivative · entry 5 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,180 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 1,050 | $0.00 | $0.00 |
DisclosureSEC source: 0002005382-26-000002 · wk-form4_1773346616.xml · nonDerivative · entry 4 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2023. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 212 | $60.13 | $12,747.56 |
DisclosureSEC source: 0002005382-26-000002 · wk-form4_1773346616.xml · nonDerivative · entry 3 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,243 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 94 | $0.00 | $0.00 |
DisclosureSEC source: 0002005382-26-000002 · wk-form4_1773346616.xml · nonDerivative · entry 2 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,455 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:17 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 838 | $0.00 | $0.00 |
DisclosureSEC source: 0002005382-26-000002 · wk-form4_1773346616.xml · nonDerivative · entry 1 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2022. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 7,531 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · derivative · entry 18 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,531 Underlying: Common Stock, $0.10 par value · 7,531 shares Expires 2028-03-10 F13 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2028, subject to certification of performance results by the Board. F13 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2028, subject to certification of performance results by the Board. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 5,015 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · derivative · entry 17 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 5,015 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_price: Each performance share converted into one share of common stock upon distribution in the first quarter of 2025 in accordance with the terms of the award and certification of performance results by the Board. F6 · derivative.exercise_date: Amount represents distribution of performance shares earned under the 2022-2024 Long-Term Performance Award. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 5,021 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · derivative · entry 16 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,021 Underlying: Common Stock, $0.10 par value · 5,021 shares Expires 2028-03-10 F10 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout. F11 · derivative.exercise_date: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 1,050 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · derivative · entry 15 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,102 Underlying: Common Stock, $0.10 par value · 1,050 shares Expires 2027-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F5 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2023. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 835 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · derivative · entry 14 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 838 Underlying: Common Stock, $0.10 par value · 835 shares Expires 2026-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F4 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2022. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 546 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · derivative · entry 13 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 546 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2021. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,359 | $63.11 | $85,766.49 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · nonDerivative · entry 12 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,711 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 1,850 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · nonDerivative · entry 11 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,070 F7 · shares: Adjustment to award based on the performance factor applied in accordance with the terms of the award and certification of performance results by the Board. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 5,015 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · nonDerivative · entry 10 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Amount represents distribution of performance shares earned under the 2022-2024 Long-Term Performance Award. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 374 | $63.11 | $23,603.14 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · nonDerivative · entry 9 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,905 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 179 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · nonDerivative · entry 8 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,279 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 1,050 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · nonDerivative · entry 7 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2023. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 296 | $63.11 | $18,680.56 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · nonDerivative · entry 6 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,408 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 146 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · nonDerivative · entry 5 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,704 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 835 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · nonDerivative · entry 4 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2022. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 219 | $63.11 | $13,821.09 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · nonDerivative · entry 3 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,015 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 38 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · nonDerivative · entry 2 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,234 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 01:31 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 546 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-25-000065 · wk-form4_1741829503.xml · nonDerivative · entry 1 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2021. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 7,546 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000067 · wk-form4_1710288103.xml · derivative · entry 16 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,546 Underlying: Common Stock, $0.10 par value · 7,546 shares Expires 2027-03-10 F13 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2027. F13 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2027. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 3,268 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000067 · wk-form4_1710288103.xml · derivative · entry 15 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 3,268 shares Expires 2024-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2024, subject to a Total Shareholder Return. F12 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2024, subject to a Total Shareholder Return. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 5,031 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000067 · wk-form4_1710288103.xml · derivative · entry 14 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,031 Underlying: Common Stock, $0.10 par value · 5,031 shares Expires 2028-03-10 F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F10 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherMarket Share Units · Derivative | 1,050 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000067 · wk-form4_1710288103.xml · derivative · entry 13 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,152 Underlying: Common Stock, $0.10 par value · 1,050 shares Expires 2027-03-10 F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F11 · shares: Represents the cancellation of one-quarter of market share units granted on March 10, 2023 due to the 80% minimum payout factor not being achieved. F10 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherMarket Share Units · Derivative | 835 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000067 · wk-form4_1710288103.xml · derivative · entry 12 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,673 Underlying: Common Stock, $0.10 par value · 835 shares Expires 2026-03-10 F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F9 · shares: Represents the cancellation of one-quarter of market share units granted on March 10, 2022 due to the 80% minimum payout factor not being achieved. F10 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 544 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000067 · wk-form4_1710288103.xml · derivative · entry 11 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 546 Underlying: Common Stock, $0.10 par value · 544 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2021. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 539 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000067 · wk-form4_1710288103.xml · derivative · entry 10 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 539 shares Expires 2024-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 10, 2020. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 917 | $53.79 | $49,325.43 |
DisclosureSEC source: 0000014272-24-000067 · wk-form4_1710288103.xml · nonDerivative · entry 9 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,726 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 1,138 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000067 · wk-form4_1710288103.xml · nonDerivative · entry 8 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,643 F6 · shares: Adjustment to Award based on the performance factor applied in accordance with the terms of the Award and certification of performance results by the Board. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 3,268 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000067 · wk-form4_1710288103.xml · nonDerivative · entry 7 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Amount represents distribution of performance shares earned under the 2021-2023 Long-Term Performance Award. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 194 | $53.79 | $10,435.26 |
DisclosureSEC source: 0000014272-24-000067 · wk-form4_1710288103.xml · nonDerivative · entry 6 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 513 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 94 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000067 · wk-form4_1710288103.xml · nonDerivative · entry 5 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 707 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 544 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000067 · wk-form4_1710288103.xml · nonDerivative · entry 4 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2021. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 197 | $53.79 | $10,596.63 |
DisclosureSEC source: 0000014272-24-000067 · wk-form4_1710288103.xml · nonDerivative · entry 3 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257 F3 · shares: Shares withheld for payment of taxes upon vesting of awards. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 85 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000067 · wk-form4_1710288103.xml · nonDerivative · entry 2 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 454 F2 · shares: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:01 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 539 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-24-000067 · wk-form4_1710288103.xml · nonDerivative · entry 1 Hoch Lynelle · CIK 0002005382 · President, Cell Therapy Org. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter of market share units granted on March 10, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.